5 Stocks to Watch: Week of 2/10/2025

Happy Valentine’s Day, a little bit early! Here’s something even better than a box of chocolates: a list of stocks that we’re loving right now (and we think you will, too). Some highlights?

• Boston Scientific Corp. (NYSE: BS) is a leading medical device provider that could see superior performance in a volatile market.
• News about refocusing on its core business and a potential new headquarters location have investors buzzing about Walmart Inc. (NYSE: WMT).
• Emcor Inc. (NYSE: EME) is a past Stock of the Week selection that could see significant upside in the coming year.
• Royal Caribbean Cruises Ltd (NYSE: RCL) racks up Strong Buy ratings despite tariff fears.
• Analysts believe that Amneal Pharmaceuticals Inc (NASDAQ: AMRX) could see 50% or more upside in the next year.

Oh, and another little gift, in case you're interested, courtesy of Seeking Alpha… ♥️

From February 7-15, WallStreetZen readers can enjoy a time-exclusive offer from leading stock research platform Seeking Alpha: $50 off Alpha Picks AND get 60 days of free Premium! Unlock the incredible value of our Alpha Picks portfolio (up +177% since July 2022) while also experiencing everything Seeking Alpha Premium has to offer. Get the offer today.

Let's get to it:

1- Boston Scientific Corp. (NYSE: BSX) 

When arteries get clogged, Boston Scientific Corp.’s Taxus Stent can help open them. But there’s more to the company than its signature stent — the company manufactures medical devices used for radiology, cardiology, and neuromodulation. Considered a dynamic player in the MedTech world, analysts are bullish about not only the sector but the stock in the coming year. 

Zen Rating:  A (Strong Buy) — see full analysis >  

Recent Price:  $105.02 — get current quote > 

Max 1-year forecast: $122.00

Why we’re watching:

• BSX enjoys a Strong Buy consensus among the 17 analysts we track issuing ratings, with a max forecast of $119. See the ratings
• A recent bullish move? Jayson Bedford of Raymond James (a top 12% analyst) recently raised their price target on BSX 17.8% from $101 to $119 on 1/31, while maintaining a Strong Buy rating. 
• This move was made in advance of BSX’s earnings, which were announced on 2/5.
• In a backgrounder, Bedford made three points: 1) Boston Scientific remains one of the most dynamic companies in MedTech. 2) Its growth profile is unique within its cap range, justifying a premium multiple. 3) Raymond James expects the stock to be volatile but nevertheless sees it as one of the top performers in its sector.
• After a review of 115 factors proven to drive stock growth, BSX earns a Zen Rating of A, putting it in the top 5% of the thousands of stocks we track on WallStreetZen. 
• The Zen Rating is built on Component Grades, and BSX’s areas of strength lie in four key areas: Growth, Sentiment, and Safety. However, the most compelling is an above-average grade from our proprietary AI rating, which uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results. This combination of strong scores indicates a watchlist-worthy stock. (See all 7 Zen Component Grades here >)

2- Walmart Inc. (NYSE: WMT)  

We probably don’t have to explain what Walmart is — after all, it’s one of the largest retailers and grocery chains in the world. While its solid balance sheet and history of earnings beats are nothing to sneeze at, Wall Street pros are currently excited about the company’s new membership model, which could drive higher profits in 2025.

Zen Rating:  B (Buy) — see full analysis >  

Recent Price:  $102.85 — get current quote > 

Max 1-year forecast: $115.00

Why we’re watching:

• WMT has strong support among the 27 analysts we track issuing ratings: 18 Strong Buy ratings, 8 Buy, and 1 Hold rating. No Sell or Strong Sell ratings. See the ratings
• In the past week, Michael Lasser of UBS (a top 7% analyst) maintained a Strong Buy rating and raised their price target on the stock 13% from $100 to $113 on 1/31. 
• Lasser’s update came in advance of the company’s earnings announcement, expected on 2/20. Lasser said that "Walmart's membership businesses, Walmart Plus and Sam's Club, should be a significant growth driver for the enterprise, with membership alone providing 2% to 3% EPS growth to Walmart's overall algorithm.
• Looking ahead, the analyst membership revenue could contribute $5.8B in CY 2026 "in an upside case."
• Our Zen Rating model agrees that WMT is one to watch. The stock has an overall B rating, meaning it’s in a class of outperformers that have historically averaged 19.88% annual returns. 
• The Component Grades that make up that overall score are solid. WMT has a Momentum rating of A — this is our proprietary metric that helps investors identify stocks on an upward trajectory likely to continue. WMT also has above-average ratings for Financials, Sentiment, and Safety. Let’s focus on that last one for a minute: Safety. it’s not common to find stocks that score so well in both Momentum and Safety. For this reason, WMT is a compelling watch for investors who want growth but want to minimize risk. (See all 7 Zen Component Grades here >)

3- Emcor Inc. (NYSE: EME)

Emcor is a leading specialty construction firm with expertise in power transmission, voice & data communications and fiber optics. This means they are riding some serious growth trends which helps explain the 57% year over year earnings growth. 

Zen Rating:  A (Strong Buy) — see full analysis >  

Recent Price:  $467.17 — get current quote > 

Max 1-year forecast: $600.00 

Why we’re watching:

• EME is a recent Stock of the Week … And it’s still worth watching. According to our resident stock expert, Zen Investor Editor-in-Chief Steve Reitmeister, EMCOR (EME) is “not a household name. But that ‘under the radar’ stature allows us to scoop up this growth stock at very attractive levels. Especially after the recent pullback in shares.” In a recent article, he expanded — here are some highlights:
• EME has had 10 straight beat and raise earnings reports that propelled shares 5X since the middle of 2022. This is where you have to dig into the fundamentals to appreciate the nature of the firm…
• EME has an overall “A” rating, which means it's a Strong Buy because it’s in the top 5% of all the stocks we analyze across 115 different factors. 
• What really jumps off the charts for EME is the top 3% showing for the 26 factors of Financial strength we review. This means it is an incredibly well-run company…the kind of company that is likely to produce more beat and raise earnings reports in the future that propels shares even higher. 
• What also stands out for EME with the Zen Ratings is how there is no weakness to be found. In most categories they are in the top 25% of stocks like Value (learn more here), Growth, Momentum and Sentiment. (See the full Zen Ratings analysis for EME here >)

4- Royal Caribbean Cruises Ltd (NYSE: RCL)

A Royal Caribbean Cruise sure sounds relaxing — but in case you’re constrained by your checkbook, consider that investing in RCL stock a year ago would have netted you a 118.40% return. Although it is currently trading at an all-time high, a pullback doesn’t seem likely, as the business recently released a standout quarterly report.

Zen Rating: B (Buy) — see full analysis >  

Recent Price:  $270.20 — get current quote > 

Max 1-year forecast:  $310.00

Why we’re watching:

• At present, RCL stock is a strong consensus Strong Buy. In total, 16 analysts track the stock — 10 deem it a Strong Buy, 4 rated it a Buy, and only 2 have given it a Hold rating. See the ratings
• Christopher Stathoulopoulos, a Susquehanna researcher (a top 3% rated analyst), maintained a prior Strong Buy rating, but increased his price target from $245 to $305 on January 29. 
• The analyst noted that the company's debut in the river cruise market through its premium brand, Celebrity Cruises, for which bookings are being accepted this year, gives Royal Caribbean Cruises access to a rapidly expanding market.
• In a similar vein, John Staszak of Argus Research (a top 12% rated analyst) opined that Wave Season (Christmas through March) is off to a great start, which bodes well for ongoing high demand and could lead to better-than-expected profits and revenue.
• RCL stock carries a Zen Rating of B — historically, this distinction has equated to an average annual return of 19.88%.
• In terms of Component Grade scores, Momentum is Royal Caribbean’s strong suit — as the stock is ranked in the top 5% according to this factor. (See all 7 Zen Component Grades here >)

5- Amneal Pharmaceuticals Inc (NASDAQ: AMRX)

It might not have the name recognition that some larger pharma companies do, but this mid-cap stock has provided an impressive yearly return. Analysts are almost unanimously bullish on Amneal Pharmaceuticals — and with a strong product pipeline and promising developments in terms of drug approval, this Bridgewater-based business seems to be gearing up for a strong showing in 2025.

Zen Rating:  A (Strong Buy) — see full analysis >  

Recent Price: $7.97 — get current quote > 

Max 1-year forecast: $12.00

Why we’re watching:

• Analyst support: Of the 4 stock analysts who track AMRX and issue ratings for it, 3 deem it a Strong Buy — and only 1 rates it a Hold. See the ratings
• Notably, David Amsellem (a top 14% rated analyst) of Piper Sandler, recently increased his price target for AMRX stock to $11 from $9.
• Ansellem maintained a prior Strong Buy rating, emboldened by the company’s 25% earnings per share (EPS) beat last quarter. Amneal also beat revenues last time around — and the business will hold its next earnings call on February 28.
• In addition, the Food and Drugs Administration (FDA) recently accepted a new drug application (NDA) from the company for IPX203 — a novel treatment for Parkinson’s disease, as well as an extended-release version of its Alzheimer’s disease treatment, Memantine.
• AMRX stock carries a Zen Rating of A. Since the early 2000s, stocks that carry this distinction have provided an average annual return of 32.52%.
• In terms of Component Grade scores, Amneal Pharmaceuticals has two particularly bright spots — its Sentiment rating, where ARMX stock is ranked in the 97th percentile (here’s why that matters). For its Value rating, it ranks in the top 7% of all the stocks we track. (See all 7 Zen Component Grades here >)

What to Do Next?

• Watch “Zen Ratings Revolution” to Unlock +32.52% Annual Gains >
• Upgrade Your Investing - Start Your Premium Trial Now! >
• Discover Zen Investor portfolio to Find More 100%+ Stock Winners>

Want to get in touch? Email us at news@wallstreetzen.com.